Last reviewed · How we verify
Venous varices — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Asclera | POLIDOCANOL | Provensis | Sclerosing Agent [EPC] | 2010-01-01 | ||
| Sotradecol | SODIUM TETRADECYL SULFATE | Elkins Sinn | tetradecyl sulfate | 1946-01-01 | ||
| Asclera | Asclera | Massachusetts General Hospital |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Elkins Sinn · 1 drug in Venous varices
- Massachusetts General Hospital · 1 drug in Venous varices
- Provensis · 1 drug in Venous varices
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Venous varices:
- Venous varices treatment updates — RSS
- Venous varices treatment updates — Atom
- Venous varices treatment updates — JSON
Cite this brief
Drug Landscape (2026). Venous varices — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/venous-varices. Accessed 2026-06-10.
Related
- Venous varices full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing